合成方法和治疗潜力的印度醇-3-碳醇 (I3C) 和其衍生物
Federica Centofanti1, Alessandro Buono2, Michele Verboni2
1Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy.
Pharmaceuticals (Basel, Switzerland)
|June 1, 2023
概括
在布拉西卡植物蔬菜中发现的印度尔-3-碳醇 (I3C) 显示出有前途的抗瘤和抗病毒活性. 进一步的研究探讨了它的合成,机制,以及对癌症和呼吸系统疾病的潜在影响.
科学领域:
- 药理学和自然产品化学化学
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 印醇-3-碳醇 (I3C) 是一种生物活性化合物,来源于布拉西卡植物蔬菜.
- I3C及其衍生物已经证明了重要的生物和药理性质.
- 之前的研究表明I3C的潜在抗瘤和抗病毒作用.
研究的目的:
- 分析I3C及其衍生物的生物合成和合成.
- 通过体外和体外研究来评估I3C及其衍生物的抗瘤和抗病毒活性.
- 研究这些化合物在疾病预防和治疗中的作用机制和潜在的社会影响.
主要方法:
- 对I3C和衍生品的生物合成途径和合成程序的审查.
- 在体外测定和体内测试的分析,以评估生物活性.
- 检查机理学研究和潜在的治疗应用.
主要成果:
- I3C及其衍生物可以通过各种生物合成和合成途径获得.
- 来自体外和体内研究的证据支持这些化合物的抗瘤和抗病毒潜力.
- 了解它们的作用机制对于它们的治疗发展至关重要.
结论:
- I3C及其衍生物在预防和治疗各种疾病,特别是癌症和呼吸道疾病方面具有显著的前景.
- 需要对它们的合成,机制和临床应用进行进一步的研究.
- 这些天然化合物可能对公共健康产生重大积极的社会影响.
关键词:
印度尔3 - 碳醇.它具有抗癌活性,具有抗癌活性.抗病毒活动的抗病毒活性.在体外测定试验 (in vitro assays) 中进行测试.在生物体内测试试验.自然产品是自然产品的产品.植物化学品 植物化学品更多相关视频
相关概念视频
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
328
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
328
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


